Dynogen Pharmaceuticals, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dynogen Pharmaceuticals, Inc.
Astellas calls time on ex-Dynogen US facility as it tidies R&D network
Astellas is to close down a small research subsidiary in the US by the end of this year, as it looks to control costs and rationalise its corporate R&D effort.
Biotechs Target the GI Tract
Regulatory risk and a mature market for some indications have driven Big Pharma players from the gastrointestinal space. That signals possible biotech opportunity. In this issue, we profile Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences.
2010 Scrip 100 - Survivors of the shakeout
Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.
Alnara Pharmaceuticals makes appointment
Alnara Pharmaceuticals, a US company developing non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, has appointed Dr Lee Brettman to the newly created position of chief medical officer. He has almost 20 years' pharmaceutical industry leadership experience; before joining Alnara, Dr Brettman was the founder, president and CEO of Dynogen Pharmaceuticals. He has also worked at Oxford Bioscience Partners and Millennium Pharmaceuticals.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals